DIMS and INA Started a Collaboration on Nonclinical Contract Study Service
DIMS Institute of Medical Science Inc. (DIMS, Ichinomiya, AICHI, President: Seiko Tamano) and Ina Research Inc. (INA, Ina, NAGANO, President and CEO: Kenshi Nakagawa) announce that the companies have started collaboration on nonclinical contract study service as of 5 October, 2020.Based on collaboration agreement between DIMS and INA, through INA by secondary consignment DIMS will be able to provide customers with services that DIMS could not provide before; Nonclinical safety studies including non-rodent general toxicity studies, safety pharmacology studies, in vitro genotoxicity studies, and reproduction toxicity studies. As a result, DIMS will build the one-stop services for nonclinical development of pharmaceuticals; receiving an order of nonclinical safety studies as a package necessary for clinical introduction/new drug approval of pharmaceuticals and preparing submission dossier such as CTD, IND/CTA documents, and Investigator’s Brochure.
On the other hand, for INA, DIMS will provide contracts related to medium-term carcinogenicity tests, which is the core competence of DIMS.
Through this collaboration, we, DIMS and INA, believe that we will be able to further enhancement of customer service by sharing the strengths of both companies, and by complementing necessary items mutually. We will continue discussions to improve the quality of customer service.
Please contact for DIMS
https://en.dims.co.jp/contact.html
TEL: +81-586-51-1201
